Separate Results of Metronomic Therapy With Cyclophosphan And Pazopanib in the Palliative Treatment of Recurrent Platinum-Resistant Ovarian Cancer
Keywords:
ovarian cancer, metronomic therapy, pazopanib, ascites
Abstract
Ascites in ovarian cancer is a common complication. Abdominal effusion may occur in the first stage of tumour development, in advanced disease, and may manifest recurrence after radical treatment. If surgery is performed, abdominal flushes and a peritoneal biopsy must be taken to detect malignant cells - it is so common for ovarian tumours to coexist with peritoneal metastases.
References
1. Абдурахмонов Ж. А., Рахимов Н. М., Шаханова Ш. Ш. Современный Взгляд На Асцит При Раке Яичников //Журнал Биомедицины И Практики. – 2022. – Т. 7. – №. 4.
2. Бабаев С. и др. Assessment of the state of immunity in patients with tumors //in Library. – 2021. – Т. 21. – №. 2. – С. 218-225
3. Рахимов Н. М. И др. Механизм развития перитонеального злокачественного асцита при рецидиве рака яичника //Клиническая и экспериментальная онкология. – 2020. – №. 4. – С. 45-49
4. Iroda M., Ruzikulov F., Nodir R. Tolerance is the Basic Principle of Observing Human Rights in Relations between Nations and Religion //American Journal of Social and Humanitarian Research. – 2022. – Т. 3. – №. 5. – С. 186-189.
5. H.-J. Choi, G.N.A. Pena, S. Pradeep, M.S. Cho, R.L. Coleman, A.K. Sood, Anti-vascular therapies in ovarian cancer:moving beyond anti-VEGF approaches, CancerMetastasis Rev. 34 (1) (2015 Mar) 19–40.]
6. M.Markman, K.Webster, K. Zanotti, G. Peterson, B. Kulp, J. Belinson, Survival following the documentation of platinumand taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials, Gynecol. Oncol. 93 (3) (2004 Jun 1) 699–701.
7. E. Pujade-Lauraine, F. Hilpert, B.Weber, et al., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial, J. Clin. Oncol. 32 (13) (2014 May 1) 1302–1308, https://doi.org/10.1200/JCO.2013.51.4489 (Epub 2014 Mar 17)
8. Saidkulov B. et al. Recurrent ovarian cancer: mechanisms of development of peritoneal malignant ascites //European Journal of Molecular and Clinical Medicine. – 2020. – Т. 7. – №. 2. – С. 2423-2428.
9. S.P. Trachana, E. Pilalis, N.G. Gavalas, et al., The development of an angiogenic protein “signature” in ovarian cancer ascites as a tool for biologic and prognostic profiling, PLoS One 11 (6) (2016 Jun 3) e0156403, https://doi.org/10.1371/journal.pone. 0156403 PMID: 27258020; PMCID: PMC4892506
10. S. Yamamoto, I. Konishi, M. Mandai, H. Kuroda, T. Komatsu, K. Nanbu, et al., Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels, Br. J. Cancer 76 (9) (1997) 1221–1227
11. M. Zhang, T. Liu, B. Xia, C. Yang, S. Hou,W. Xie, G. Lou, Platelet-derived growth factor D is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer, Int
2. Бабаев С. и др. Assessment of the state of immunity in patients with tumors //in Library. – 2021. – Т. 21. – №. 2. – С. 218-225
3. Рахимов Н. М. И др. Механизм развития перитонеального злокачественного асцита при рецидиве рака яичника //Клиническая и экспериментальная онкология. – 2020. – №. 4. – С. 45-49
4. Iroda M., Ruzikulov F., Nodir R. Tolerance is the Basic Principle of Observing Human Rights in Relations between Nations and Religion //American Journal of Social and Humanitarian Research. – 2022. – Т. 3. – №. 5. – С. 186-189.
5. H.-J. Choi, G.N.A. Pena, S. Pradeep, M.S. Cho, R.L. Coleman, A.K. Sood, Anti-vascular therapies in ovarian cancer:moving beyond anti-VEGF approaches, CancerMetastasis Rev. 34 (1) (2015 Mar) 19–40.]
6. M.Markman, K.Webster, K. Zanotti, G. Peterson, B. Kulp, J. Belinson, Survival following the documentation of platinumand taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials, Gynecol. Oncol. 93 (3) (2004 Jun 1) 699–701.
7. E. Pujade-Lauraine, F. Hilpert, B.Weber, et al., Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial, J. Clin. Oncol. 32 (13) (2014 May 1) 1302–1308, https://doi.org/10.1200/JCO.2013.51.4489 (Epub 2014 Mar 17)
8. Saidkulov B. et al. Recurrent ovarian cancer: mechanisms of development of peritoneal malignant ascites //European Journal of Molecular and Clinical Medicine. – 2020. – Т. 7. – №. 2. – С. 2423-2428.
9. S.P. Trachana, E. Pilalis, N.G. Gavalas, et al., The development of an angiogenic protein “signature” in ovarian cancer ascites as a tool for biologic and prognostic profiling, PLoS One 11 (6) (2016 Jun 3) e0156403, https://doi.org/10.1371/journal.pone. 0156403 PMID: 27258020; PMCID: PMC4892506
10. S. Yamamoto, I. Konishi, M. Mandai, H. Kuroda, T. Komatsu, K. Nanbu, et al., Expression of vascular endothelial growth factor (VEGF) in epithelial ovarian neoplasms: correlation with clinicopathology and patient survival, and analysis of serum VEGF levels, Br. J. Cancer 76 (9) (1997) 1221–1227
11. M. Zhang, T. Liu, B. Xia, C. Yang, S. Hou,W. Xie, G. Lou, Platelet-derived growth factor D is a prognostic biomarker and is associated with platinum resistance in epithelial ovarian cancer, Int
Published
2023-08-28
How to Cite
Shavkatovna , S. S., Amrilloevich , A. Z., Nodir , R., & Talibova, N. A. (2023). Separate Results of Metronomic Therapy With Cyclophosphan And Pazopanib in the Palliative Treatment of Recurrent Platinum-Resistant Ovarian Cancer. Central Asian Journal of Medical and Natural Science, 4(4), 557-559. Retrieved from https://cajmns.centralasianstudies.org/index.php/CAJMNS/article/view/1749
Section
Articles
